Aptevo Forms Strategic Radiopharmaceutical Collaboration with Niowave, Secures $500K Equity Investment
APVO sits 30% above its 52-week low of $3.8.
Summary
Aptevo Therapeutics has entered into a strategic 50/50 collaboration with Niowave to develop radiopharmaceutical oncology programs, accompanied by an initial $500,000 equity investment from Niowave.
Key Events · M&A and Partnerships · APVO
-
Strategic Collaboration Launched
Aptevo Research and Development LLC, a subsidiary of Aptevo, entered into a 50/50 collaboration agreement with Niowave, Inc. to develop up to three radiopharmaceutical oncology programs, combining Aptevo's proprietary molecules (including APVO455) with Niowave's radioisotopes (including Actinium-225).
-
Initial Equity Investment Secured
Niowave made an initial equity investment of approximately $500,000 in Aptevo, purchasing 98,522 shares of common stock and accompanying warrants to purchase 53,201 shares. The combined purchase price was $5.075 per share, with warrants exercisable at $8.00 per share.
-
Significant Ownership Stake
The initial investment gives Niowave an approximate 7.9% ownership stake in Aptevo, with the potential to increase its beneficial ownership up to 19.99% through warrant exercises and additional private placements of up to 97,373 shares.
-
Expansion into Radiopharmaceuticals
This collaboration marks Aptevo's strategic expansion into radiopharmaceutical-based therapeutic development, leveraging its ADAPTIR™ and ADAPTIR-FLEX™ platform technologies in a new, high-growth area of oncology.
Analysis · APVO · Life Sciences
This filing details a significant strategic collaboration for Aptevo, expanding its development into radiopharmaceutical oncology, a high-growth area. The partnership with Niowave, a leader in radioisotope production, provides critical expertise and resources. The accompanying $500,000 equity investment, while dilutive, is crucial for Aptevo, which recently disclosed a 'going concern' warning. The investment, representing over 8% of Aptevo's market cap, and the potential for further equity purchases, provide much-needed capital and a strong vote of confidence from a strategic partner, validating Aptevo's technology and extending its operational runway.
How filings like this one have moved
In the 30 days to Aug 23, 2026, 43.4% of the 1019 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.13%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, APVO was trading at $4.93 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6M. The 52-week trading range was $3.80 to $235.98. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.